Data Sheet (Cat.No.T67828)

TargetMol

Enerisant

Chemical Properties



CAS No. : 1152747-82-4

Formula: C22H30N4O3

Molecular Weight: 398.50

Storage: Store at low temperature
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Actual storage temperature shall be subject to the COA.

Biological Description

Description	Enerisant (TS-091) is an orally active, selective and potent histamine H3 receptor antagonist that modulates histamine H3 receptors in mice in a dose-dependent manner. Enerisant promotes pro-cognitive effects and reverses scopolamine-induced cognitive deficits.
Targets(IC50)	Histamine Receptor
In vivo	In the male SD rat model of R-α-methylhistamine-induced dipsogenia, Enerisant (oral, single dose, 0.1, 0.3, and 1 mg/kg) attenuated the dipsogenic response[1].

Solubility Information

Solubility	DMSO: 80 mg/mL (200.75 mM),Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)
In vivo Formulation	10% DMSO+40% PEG300+5% Tween 80+45% Saline: 3.3 mg/mL (8.28 mM),Sonication is recommended. *Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.*

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	2.5094 mL	12.5471 mL	25.0941 mL
5 mM	0.5019 mL	2.5094 mL	5.0188 mL
10 mM	0.2509 mL	1.2547 mL	2.5094 mL
50 mM	0.0502 mL	0.2509 mL	0.5019 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

Hino N, et al. A novel potent and selective histamine H3 receptor antagonist enerisant: in vitro profiles, in vivo receptor occupancy, and wake-promoting and procognitive effects in rodents. Journal of Pharmacology and Experimental Therapeutics, 2020, 375(2): 276-285.